Articles tagged with Ovarian Cancer
A long-term study found that women with BRCA1 and BRCA2 genetic mutations significantly reduced their risk of breast and ovarian cancer with preventive surgeries. Risk-reducing mastectomies and removal of the fallopian tubes and ovaries lowered cancer risks, including those with prior breast cancer.
Prophylactic mastectomy and salpingo-oophorectomy significantly reduce breast and ovarian cancer risks in women with BRCA1/2 mutations. The study found that risk-reducing mastectomy decreased breast cancer risk, while salpingo-oophorectomy lowered ovarian cancer risk.
Women with a family history of breast or ovarian cancer can benefit from prophylactic surgeries to remove ovaries, fallopian tubes, or breasts, increasing survival rates and eliminating risk. Genetic testing is crucial for identifying the BRCA1 and BRCA2 genes, which significantly increase cancer risk.
The study found that depleting SIK2 from ovarian cancers sensitized the cells to paclitaxel, making it more effective in stopping cancer growth. Levels of SIK2 protein are increased in approximately 30 percent of ovarian cancers and associated with poorer survival rates.
Researchers have discovered a protein called Salt Inducible Kinase 2 (SIK2) that plays a key role in regulating cell division and may be an attractive target for treating ovarian cancer. Combination therapies targeting different phases of the cell cycle are highly desirable for optimal cancer treatment.
Researchers found that EZH2 promotes tumor growth by shutting down genes that block formation of new blood vessels. Silencing EZH2 in ovarian cancer tumors reduced average tumor weight by 62% and increased programmed death of tumor cells.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
A recent study suggests that a new drug, Olaparib, can reduce tumor size in women with advanced hereditary ovarian and breast cancers, offering a promising targeted therapy approach. The Phase II trials showed significant shrinkage in tumor size and relatively mild toxicities.
The new test uses mass spectrometry to analyze metabolites in a single drop of blood serum, accurately identifying women with ovarian cancer in all tested patients. Further testing will be conducted on 500 patients to confirm the results and explore its potential for detecting other types of cancers.
Researchers at Yale University have discovered a genetic marker that can help predict ovarian cancer risk. The KRAS-variant was found in 25% of all ovarian cancer patients and 61% of those with a family history of breast and ovarian cancer, suggesting it may be a new marker for high-risk families.
A new study reveals that shorter leukocyte telomere length is associated with a significantly increased risk of developing cancer and dying from cancer. Participants with the shortest telomere lengths had approximately three times the risk of cancer compared to those in the longest group.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
Two phase-2 trials demonstrate the efficacy of olaparib in treating advanced ovarian and breast cancer in patients with BRCA1 or BRCA2 mutations. The higher dose of olaparib showed better treatment response rates compared to the lower dose, with ORR of 33% and 41% respectively.
Researchers at Arizona State University and Fred Hutchinson Cancer Research Center develop a new method to identify biomarkers for ovarian cancer using antibodies. They found 19 distinct scFvs that selectively bound to proteins exclusively found in ovarian cancerous blood serum, providing potential for significant improvements in patie...
A phase I clinical trial of the combination of decitabine and carboplatin has shown promising results in treating late-stage ovarian cancer, with four patients experiencing no disease progression after six months. The treatment regimen has been found to be well-tolerated, with mild adverse reactions.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
Researchers found that CA-125 change over time can detect invasive, high-grade ovarian cancers at curable stages in post-menopausal women. The study identified a promising first step towards screening, but acknowledges the need for further research and a large-scale randomized trial to confirm the findings.
Researchers found that flaxseed-enriched diets decreased late-stage ovarian tumor severity and increased survival rates in hens. The study also showed improved weight control and reduced metastatic spread in hens fed the flaxseed diet, suggesting potential benefits for human ovarian cancer treatment.
Researchers found that curcumin nanoparticles, delivered via nanoparticles, increased the sensitivity of resistant ovarian cancer cells to chemotherapy and radiation. The treatment enables lower doses of cisplatin and radiation, improving therapeutic outcomes without increasing toxicity.
Fox Chase researchers have discovered that early ovarian cancers arise in inclusion cysts of the ovary. The team found gene expression patterns and extra chromosomes in cells from these cysts compared to normal surface epithelium cells.
Researchers have found that patients with hereditary ovarian cancer are more likely to experience secondary tumours in their liver and spleen, despite better overall prognosis. A new approach suggests testing these patients for BRCA1 and BRCA2 genes to ensure tailored treatment.
Researchers have identified a new breast and ovarian cancer susceptibility gene, RAD51C, in a German study. The gene is associated with a high risk of breast and ovarian cancer, particularly in familial cases.
The Anne Rita Monahan Foundation has raised $50,000 for ovarian cancer research at the Translational Genomics Research Institute (TGen). Funds from the 2nd annual Tea for TEAL event will support the development of a reliable screening test and precision therapy for ovarian cancer.
Researchers at Fox Chase Cancer Center have isolated an engineered antibody, GS45, that targets the Müllerian Inhibiting Substance Type II Receptor on ovarian cancer cells. This unique target is scarce in normal tissue, reducing the risk of side effects associated with traditional targeted therapies.
Researchers found that stress-activated protein protects fugitive ovarian cancer cells from programmed death, allowing them to escape the primary tumor and metastasize. The study suggests that restoring cancer cells' vulnerability to anoikis could suppress tumor growth and metastasis.
Researchers find that stress hormones can protect ovarian cancer cells from anoikis, promoting tumor growth. Higher levels of activated FAK are linked to accelerated mortality in ovarian cancer patients.
Chronic stress accelerates tumor growth in ovarian cancer patients by protecting cells from anoikis, a process that allows tumor cells to survive and grow. Stress hormones norepinephrine and epinephrine activate the protein FAK, leading to accelerated mortality.
A recent study published in the Journal of Clinical Oncology found that women with breast cancer before age 55 who carry an inherited mutation in BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite their initial tumor. The study revealed a higher risk of contralateral breast cancer among younger women wit...
Researchers from the University of Gothenburg found that women with a known Western Swedish mutation in the BRCA1 gene have an increased risk of developing ovarian cancer. The study suggests that women without this mutation do not face an elevated risk, and provides clarity for targeted screenings.
Despite progress in cancer research, the disease remains a leading cause of death in the US. Advances in primary prevention, early detection, and treatment have improved outcomes for many cancers, but significant challenges remain, including the need for improved therapies.
Researchers found that microRNA-31 regulates the protein IFITM-1, which contributes to chemoresistance in ovarian cancer. Identifying this microRNA could lead to a therapeutic target for overcoming chemotherapy resistance.
A new study suggests that elective removal of ovaries during hysterectomy may not be beneficial and could even increase the risk of other health problems. The study analyzed data from over 300,000 women who underwent the procedure, finding a link between oophorectomy and increased risks of coronary artery disease and hip fractures.
Researchers found that GP referrals for gynaecological investigation were delayed for older women with suspected ovarian cancer. Women over 70 years old had a 20-week wait for referral, while those aged 75-79 years had a peak wait of 24 weeks. The discrepancy may be due to differences in data recording and GPs' motivation.
Businessman-philanthropist Foster Friess will match donations up to $50,000 to support TGen's ovarian cancer research. The event has already raised nearly $38,000, with over 500 participants expected.
A new study published in the Journal of the American Dietetic Association found a strong relationship between healthy eating and prolonged ovarian cancer survival. Higher consumption of fruits, vegetables, and healthier grains was associated with improved survival rates.
Dr Clare Scott and Dr Marnie Blewitt have been awarded fellowships worth AU$1.75 million to focus on lymphoma and breast cancer, respectively. Their research aims to improve outcomes for cancer patients by harnessing the body's natural killing machinery.
POSITIVE RESULTS is a comprehensive guidebook for those at high risk of breast and ovarian cancer, providing insights into genetics, diagnosis, and treatment options. The book offers a supportive approach to navigating complex decisions, covering genetic testing, screening, mastectomy, and more.
Researchers at Georgia Tech have developed a potential new treatment against ovarian cancer using magnetic nanoparticles to attach to and remove cancer cells from the body. The technique has shown promising results in both mouse and human cancer samples.
Researchers found that ovarian cancer symptoms are not reliable for detecting the disease at an early stage. In fact, only 1 out of 100 women with symptoms will be diagnosed with ovarian cancer. This study highlights the need for better molecular markers and imaging modalities to improve screening for ovarian cancer.
Researchers at Yale University have discovered that stopping the expression of two genes Lin28 and Oct4 can reduce ovarian cancer cell growth and survival. This could lead to more effective treatments for this deadly form of cancer, which has a high recurrence rate and resistance to treatment.
Researchers discovered a noninvasive contrast-enhanced ultrasound imaging technique that can aid in the detection of early-stage ovarian cancer when combined with proteomic blood analyses. This method has shown high accuracy and the potential to save lives by detecting disease at an early stage.
Researchers found that biomarker levels began to rise 3 years before clinical diagnosis, but became substantially elevated only a year prior. While not accurate enough for early intervention, these markers are associated with modest increases in ovarian cancer risk.
A genetic signature associated with poor patient outcomes could lead to improved therapies for ovarian cancer. The study found that MAGP2, a previously unknown cancer gene, was overexpressed in tumors of patients who died more quickly.
Research from the American Journal of Pathology reveals that glycosaminoglycans contribute to skeletal abnormalities in patients with lysosomal storage diseases. Additionally, αvβ3-integrin expression improves ovarian cancer patient prognosis, while CpG DNA may be a therapeutic candidate for Alzheimer's disease treatment.
A new study finds that women with a deleterious BRCA gene mutation are diagnosed with breast cancer six years earlier than their relatives who also had the disease and/or ovarian cancer. The findings could impact how women at highest risk for breast cancer are counseled and screened in the future.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
The Fox Chase-Penn Ovarian SPORE program will focus on three central concepts in ovarian cancer: epigenetics, predictive biomarkers, and targeted therapeutics. The grant will fund five main research projects and three core facilities to support multidisciplinary research efforts.
Researchers at the University of Gothenburg have developed a new treatment that uses a radioactive substance to seek and destroy tumour cells in ovarian cancer patients. The treatment, which has shown no unwanted side-effects in an initial study, aims to provide a more effective alternative to current treatments.
A new genetic marker associated with ovarian cancer risk was discovered by a research group led by scientists from the University of Hawaii at Manoa. The marker is present among 32% of women and contributes an estimated 0.7% to ovarian cancer risk, particularly for serous carcinoma subtype.
A recent analysis of 1.2 million Swedish hospital cases reveals that heart failure is associated with poor survival rates, more deaths, and premature life-years lost compared to common cancers. Heart failure affects more men and women than most cancer types, particularly in Sweden.
A new study published in the American Cancer Society's journal finds that young women with early-stage ovarian cancer can preserve future fertility by conserving at least one ovary or the uterus. Researchers analyzed data from over 1,800 patients and found those who conserved an ovary had similar survival rates for up to five years.
Researchers developed nanoparticles that selectively delivered diphtheria toxin genes to ovarian cancer cells, slowing tumor growth and increasing lifespan by nearly four weeks. This therapy shows promise as a targeted treatment for advanced ovarian cancer.
A new gene therapy technique using nanoparticles has shown promise in suppressing ovarian tumor growth in mice, offering a potential treatment for late-stage ovarian cancer. The nanoparticles deliver a killer gene that kills cells by disrupting protein production, avoiding toxic side effects common with traditional chemotherapy.
Researchers developed a novel therapeutic delivery system that targets EphA2 protein in ovarian cancer cells, delivering chemotherapy with high specificity and reducing tumor growth by up to 98%. The therapy shows promising results in preclinical models and is expected to enter phase I clinical trials soon.
A novel immunoconjugate targeting EphA2 protein shows substantial antitumor activity in ovarian cancer cell lines and mice. The agent inhibits tumor growth by 85% compared to control, with significant effects on proliferation and apoptosis.
Current diagnostic tests for ovarian cancer are ineffective for early detection, but a new study suggests that with improved testing, tumors can be detected up to 4.3 years before diagnosis and treatment is possible. The window of opportunity for successful treatment is surprisingly long, making reliable early detection crucial.
Researchers developed models to understand the growth and progression of serous ovarian cancer, identifying key properties for a biomarker-based screening test. The study aimed to guide rational design of an early detection strategy, potentially leading to improved outcomes for women diagnosed with this aggressive type of ovarian cancer.
Early-stage ovarian tumors can remain undetectable for years due to their small size, posing a significant challenge in early detection. The study suggests that detecting these microscopic tumors within a four-year window could enable surgeons to remove them before they spread.
A subset of infiltrating monocyte-derived macrophages, expressing interleukin-10, exhibits an anti-inflammatory role in spinal cord injuries. This suggests that these cells may have a beneficial effect on recovery from such injuries.
Researchers at Dartmouth Medical School have developed a Trojan horse nanoparticles to target ovarian cancer, reprogramming protective cells into killers. The approach triggers an inflammatory immune response, directly killing tumor cells and potentially complementing current therapies.